Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 3/20 | 0.35 |
| ▸ | TERT | O14746 | 2/20 | 0.34 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TOP2A | P11388 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 2/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | NQO2 | P16083 | 2/20 | 0.32 |
| ▸ | TOP1 | P11387 | 1/20 | 0.31 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12161496 | 0.94 | P2RY12 (0.42) | KMT2AP2RY12ATMTERTNOD1 | |
| SCHEMBL12177240 | 0.90 | KMT2A (0.40) | KMT2AP2RY12NOD1ALDH1A1PPARG | |
| SCHEMBL12177260 | 0.89 | P2RY12 (0.44) | P2RY12ATMTERTNOD1TOP2A | |
| SCHEMBL9922387 | 0.88 | HRH3 (0.42) | KMT2AP2RY12TERTMCHR1 | |
| SCHEMBL13638373 | 0.87 | ATM (0.37) | ATM | |
| SCHEMBL12177214 | 0.87 | HRH3 (0.42) | KMT2AP2RY12TERTMCHR1 | |
| SCHEMBL13638604 | 0.87 | KMT2A (0.40) | KMT2AP2RY12NOD1ALDH1A1PPARG | |
| SCHEMBL13182847 | 0.87 | KMT2A (0.38) | KMT2AP2RY12NOD1ALDH1A1PPARG | |
| SCHEMBL14113579 | 0.87 | P2RY12 (0.39) | KMT2AP2RY12ATMTERTNOD1 | |
| SCHEMBL13182892 | 0.86 | HRH3 (0.43) | KMT2ATERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622474-B2 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PIGS, GP6, ASGR1 | KMT2A 3608/4885P2RY12 89/4885ATM 1434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.